Literature DB >> 20438295

Expression of multiple myeloma associated markers in bone marrow spicules using a novel immunohistochemical technique.

M Santra1, J D Shaughnessy, W T Bellamy.   

Abstract

Immunohistochemistry (IHC) is an important tool used for diagnosis and prognosis of several hematological malignancies, and it frequently is used for quantitative and qualitative analysis of expression of different protein biomarkers in tissue sections. To understand the histopathological alterations in multiple myeloma (MM), IHC analysis of bone marrow (BM) biopsy is commonly used. Owing to the harsh decalcification process generally used for processing of bone marrow biopsies, however, protein epitopes occasionally are rendered unsuitable for IHC detection. We have developed a novel technique for processing BM spicule samples into a fibrin clot matrix that allows IHC detection of MM protein markers. This method does not require decalcification and results in a consistent, reliable assay. Using paired BM spicule-clot and BM core biopsies from patients diagnosed with multiple myeloma, we studied six MM related antibodies including kappa and lambda immunoglobulin light chains, CD56, CD138, CYR61 and DKK1.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20438295      PMCID: PMC3394679          DOI: 10.3109/10520290903565978

Source DB:  PubMed          Journal:  Biotech Histochem        ISSN: 1052-0295            Impact factor:   1.718


  11 in total

Review 1.  Genomic aberrations and immunohistochemical markers as prognostic indicators in multiple myeloma.

Authors:  J Yeung; H Chang
Journal:  J Clin Pathol       Date:  2007-12-12       Impact factor: 3.411

2.  Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation.

Authors:  Gregory A Clines; Khalid S Mohammad; Yongde Bao; Owen W Stephens; Larry J Suva; John D Shaughnessy; Jay W Fox; John M Chirgwin; Theresa A Guise
Journal:  Mol Endocrinol       Date:  2006-10-26

3.  Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions.

Authors:  I B Bayer-Garner; R D Sanderson; M V Dhodapkar; R B Owens; C S Wilson
Journal:  Mod Pathol       Date:  2001-10       Impact factor: 7.842

4.  Automated colorimetric in situ hybridization (CISH) detection of immunoglobulin (Ig) light chain mRNA expression in plasma cell (PC) dyscrasias and non-Hodgkin lymphoma.

Authors:  Rose C Beck; Raymond R Tubbs; Mohamad Hussein; James Pettay; Eric D Hsi
Journal:  Diagn Mol Pathol       Date:  2003-03

Review 5.  Chromosome translocations in multiple myeloma.

Authors:  P L Bergsagel; W M Kuehl
Journal:  Oncogene       Date:  2001-09-10       Impact factor: 9.867

Review 6.  CCN proteins: multifunctional signalling regulators.

Authors:  Bernard Perbal
Journal:  Lancet       Date:  2004-01-03       Impact factor: 79.321

7.  Aberrant nuclear p53 protein expression detected by immunohistochemistry is associated with hemizygous P53 deletion and poor survival for multiple myeloma.

Authors:  Hong Chang; Joanna Yeung; Connie Qi; Wei Xu
Journal:  Br J Haematol       Date:  2007-06-07       Impact factor: 6.998

8.  Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma.

Authors:  Deborah J Heath; Andrew D Chantry; Clive H Buckle; Les Coulton; John D Shaughnessy; Holly R Evans; John A Snowden; David R Stover; Karin Vanderkerken; Peter I Croucher
Journal:  J Bone Miner Res       Date:  2009-03       Impact factor: 6.741

9.  Bone marrow trephine combined with immunohistochemistry is superior to bone marrow aspirate in follow-up of myeloma patients.

Authors:  R Joshi; D Horncastle; K Elderfield; I Lampert; A Rahemtulla; K N Naresh
Journal:  J Clin Pathol       Date:  2007-05-25       Impact factor: 3.411

10.  The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma.

Authors:  Erming Tian; Fenghuang Zhan; Ronald Walker; Erik Rasmussen; Yupo Ma; Bart Barlogie; John D Shaughnessy
Journal:  N Engl J Med       Date:  2003-12-25       Impact factor: 91.245

View more
  3 in total

1.  CYR61/CCN1 overexpression in the myeloma microenvironment is associated with superior survival and reduced bone disease.

Authors:  Sarah K Johnson; James P Stewart; Rakesh Bam; Pingping Qu; Bart Barlogie; Frits van Rhee; John D Shaughnessy; Joshua Epstein; Shmuel Yaccoby
Journal:  Blood       Date:  2014-07-24       Impact factor: 22.113

2.  The role of CCN family genes in haematological malignancies.

Authors:  J E Wells; M Howlett; L C Cheung; Ursula R Kees
Journal:  J Cell Commun Signal       Date:  2015-05-31       Impact factor: 5.782

3.  Mesenchymal stem cell contact promotes CCN1 splicing and transcription in myeloma cells.

Authors:  Julia Dotterweich; Regina Ebert; Sabrina Kraus; Robert J Tower; Franz Jakob; Norbert Schütze
Journal:  Cell Commun Signal       Date:  2014-06-25       Impact factor: 5.712

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.